Technology

IDEAYA Biosciences

$19.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.43 (-2.21%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell IDYA and other stocks, options, and ETFs commission-free!

About IDYA

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA. The listed name for IDYA is IDEAYA Biosciences, Inc. Common Stock.

CEO
Yujiro S. Hata
Employees
47
Headquarters
South San Francisco, California
Founded
2015
Market Cap
552.62M
Price-Earnings Ratio
Dividend Yield
Average Volume
474.99K
High Today
$20.75
Low Today
$18.61
Open Price
$19.46
Volume
298.40K
52 Week High
$20.75
52 Week Low
$2.95

Collections

IDYA Earnings

-$1.30
-$0.87
-$0.43
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 24, Pre-Market

You May Also Like

SQNS
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure